These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 18616968

  • 1. Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2.
    Svane IM, Pedersen AE, Nikolajsen K, Zocca MB.
    Vaccine; 2008 Aug 26; 26(36):4716-24. PubMed ID: 18616968
    [Abstract] [Full Text] [Related]

  • 2. High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer.
    Met O, Balslev E, Flyger H, Svane IM.
    Breast Cancer Res Treat; 2011 Jan 26; 125(2):395-406. PubMed ID: 20336365
    [Abstract] [Full Text] [Related]

  • 3. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.
    Hueman MT, Stojadinovic A, Storrer CE, Foley RJ, Gurney JM, Shriver CD, Ponniah S, Peoples GE.
    Breast Cancer Res Treat; 2006 Jul 26; 98(1):17-29. PubMed ID: 16758122
    [Abstract] [Full Text] [Related]

  • 4. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
    Wei Y, Sticca RP, Holmes LM, Burgin KE, Li J, Williamson J, Evans L, Smith SJ, Stephenson JJ, Wagner TE.
    Int J Oncol; 2006 Mar 26; 28(3):585-93. PubMed ID: 16465362
    [Abstract] [Full Text] [Related]

  • 5. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.
    Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R, Coukos G, DeMichele A, Araujo L, Spitz FR, Rosen M, Levine BL, June C, Zhang PJ.
    Cancer Res; 2007 Feb 15; 67(4):1842-52. PubMed ID: 17293384
    [Abstract] [Full Text] [Related]

  • 6. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
    Hoffmann TK, Donnenberg AD, Finkelstein SD, Donnenberg VS, Friebe-Hoffmann U, Myers EN, Appella E, DeLeo AB, Whiteside TL.
    Cancer Res; 2002 Jun 15; 62(12):3521-9. PubMed ID: 12067999
    [Abstract] [Full Text] [Related]

  • 7. Changes in peripheral blood level of regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2.
    Bjoern J, Brimnes MK, Andersen MH, Thor Straten P, Svane IM.
    Scand J Immunol; 2011 Mar 15; 73(3):222-33. PubMed ID: 21204893
    [Abstract] [Full Text] [Related]

  • 8. Impact of high-dose chemotherapy on antigen-specific T cell immunity in breast cancer patients. Application of new flow cytometric method.
    Svane IM, Nikolajsen K, Hansen SW, Kamby C, Nielsen DL, Johnsen HE.
    Bone Marrow Transplant; 2002 Apr 15; 29(8):659-66. PubMed ID: 12180110
    [Abstract] [Full Text] [Related]

  • 9. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
    Soleimani A, Berntsen A, Svane IM, Pedersen AE.
    Scand J Immunol; 2009 Nov 15; 70(5):481-9. PubMed ID: 19874553
    [Abstract] [Full Text] [Related]

  • 10. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.
    Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, Bepler G, Simon G, Janssen W, Lee JH, Menander K, Chada S, Gabrilovich DI.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):878-87. PubMed ID: 16467102
    [Abstract] [Full Text] [Related]

  • 11. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
    Li L, Giannopoulos K, Reinhardt P, Tabarkiewicz J, Schmitt A, Greiner J, Rolinski J, Hus I, Dmoszynska A, Wiesneth M, Schmitt M.
    Int J Oncol; 2006 Apr 01; 28(4):855-61. PubMed ID: 16525634
    [Abstract] [Full Text] [Related]

  • 12. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
    Cancer; 2009 Feb 15; 115(4):800-11. PubMed ID: 19117353
    [Abstract] [Full Text] [Related]

  • 13. Characterization of the role of CD8+T cells in breast cancer immunity following mammaglobin-A DNA vaccination using HLA-class-I tetramers.
    Bharat A, Benshoff N, Fleming TP, Dietz JR, Gillanders WE, Mohanakumar T.
    Breast Cancer Res Treat; 2008 Aug 15; 110(3):453-63. PubMed ID: 17874294
    [Abstract] [Full Text] [Related]

  • 14. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro.
    Delirezh N, Moazzeni SM, Shokri F, Shokrgozar MA, Atri M, Kokhaei P.
    Cell Immunol; 2009 Aug 15; 257(1-2):23-31. PubMed ID: 19306994
    [Abstract] [Full Text] [Related]

  • 15. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
    Chang GC, Lan HC, Juang SH, Wu YC, Lee HC, Hung YM, Yang HY, Whang-Peng J, Liu KJ.
    Cancer; 2005 Feb 15; 103(4):763-71. PubMed ID: 15637694
    [Abstract] [Full Text] [Related]

  • 16. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
    Davis ID, Chen Q, Morris L, Quirk J, Stanley M, Tavarnesi ML, Parente P, Cavicchiolo T, Hopkins W, Jackson H, Dimopoulos N, Tai TY, MacGregor D, Browning J, Svobodova S, Caron D, Maraskovsky E, Old LJ, Chen W, Cebon J.
    J Immunother; 2006 Feb 15; 29(5):499-511. PubMed ID: 16971806
    [Abstract] [Full Text] [Related]

  • 17. Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination.
    Svane IM, Nikolajsen K, Johnsen HE.
    Scand J Immunol; 2007 Oct 15; 66(4):465-75. PubMed ID: 17850592
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
    Mittendorf EA, Storrer CE, Foley RJ, Harris K, Jama Y, Shriver CD, Ponniah S, Peoples GE.
    Cancer; 2006 Jun 01; 106(11):2309-17. PubMed ID: 16596621
    [Abstract] [Full Text] [Related]

  • 19. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
    Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK.
    Clin Cancer Res; 2005 Apr 15; 11(8):3017-24. PubMed ID: 15837756
    [Abstract] [Full Text] [Related]

  • 20. CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53.
    Sørensen RB, Andersen RS, Svane IM, Engell-Noerregaard L, Hadrup SR, Balslev E, Andersen MH, thor Straten P.
    Clin Cancer Res; 2009 Mar 01; 15(5):1543-9. PubMed ID: 19223507
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.